Zobrazeno 1 - 10
of 2 350
pro vyhledávání: '"Recurrent Ovarian Cancer"'
Autor:
Lilit Harutyunyan, Evelina Manvelyan, Nune Karapetyan, Samvel Bardakhchyan, Aram Jilavyan, Gevorg Tamamyan, Armen Avagyan, Liana Safaryan, Davit Zohrabyan, Narine Movsisyan, Anna Avinyan, Arevik Galoyan, Mariam Sargsyan, Martin Harutyunyan, Hasmik Nersoyan, Arevik Stepanyan, Armenuhi Galstyan, Samvel Danielyan, Armen Muradyan, Gagik Jilavyan
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1323-1334 (2024)
Background: Annually, approximately 200 new ovarian cancer cases are diagnosed in Armenia, which is considered an upper-middle-income country. This study aimed to summarize the survival outcomes of patients with relapsed ovarian cancer in Armenia bas
Externí odkaz:
https://doaj.org/article/786ec4df7f0149208daeb599b2e0349e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundOvarian cancer (OC) is a gynecological malignancy with a high mortality rate worldwide. The unfavorable prognosis of OC is mainly attributed to the recurrent propensity. Recently, mortality from OC has exhibited a downward trend. These favo
Externí odkaz:
https://doaj.org/article/4ff894d332d1482fa431a69c4bc7e43f
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
As one lethal malignancy in women’s reproductive systems, ovarian cancer (OC) is frequently detected at an advanced phase during diagnosis. when the disease has spread widely. The absence of obvious symptoms and powerful screening tools in the earl
Externí odkaz:
https://doaj.org/article/88da4e9f92fe4dff96e85c2bdbcc0478
Publikováno v:
Gynecologic Oncology Reports, Vol 53, Iss , Pp 101374- (2024)
Introduction: Treatment for recurrent ovarian clear cell carcinoma (OCCC) is clinically challenging as response rates to traditional chemotherapy are low, and recurrence rates are high. Immunotherapy has shown promise for this ovarian cancer (OC) sub
Externí odkaz:
https://doaj.org/article/7c5a5f1a75c946cca9d9a73723bc00fd
Publikováno v:
The Egyptian Journal of Radiology and Nuclear Medicine, Vol 55, Iss 1, Pp 1-17 (2024)
Abstract Background The chronic nature of ovarian cancer and disease recurrence has a considerable impact on the assessment of follow-up strategies and treatment planning for both oncologists and radiologists. It is imperative to conduct adequate fol
Externí odkaz:
https://doaj.org/article/44f36ba4ec084aadb60d649c343bd84f
Autor:
Pedro Villarejo Campos, Susana Sánchez García, Mariano Amo-Salas, Esther García Santos, Carlos López de la Manzanara, Ana Alberca, David Padilla-Valverde, Francisco Javier Redondo Calvo, Jesús Martín
Publikováno v:
Current Oncology, Vol 31, Iss 2, Pp 660-671 (2024)
Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal
Externí odkaz:
https://doaj.org/article/0f70cf46e86e4bc8a41b35065c64fc55
Autor:
Yong Bae Kim, Hwa Kyung Byun, Chan Woo Wee, Hojin Kim, Seyoung Kim, Gowoon Yang, Jina Kim, Sang Joon Park, Jung-Yun Lee
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Efforts have been made to investigate the role of salvage radiotherapy (RT) in treating recurrent ovarian cancer (ROC). Stereotactic ablative radiation therapy (SABR) is a state-of-the-art therapy that uses intensity modulation to
Externí odkaz:
https://doaj.org/article/47fdf4fb1f1c446196ad90194e135696
Autor:
Soha Sami, Soha Talaat Hamed, Lamia Adel, Ahmed Abdel Samie Kandeel, Eman Faker Kamal, Sherihan Fakhry
Publikováno v:
The Egyptian Journal of Radiology and Nuclear Medicine, Vol 54, Iss 1, Pp 1-9 (2023)
Abstract Background 18F-fluorodeoxyglucose (FDG) PET/CT is a noninvasive imaging tool that has been used successfully for the diagnosis, staging, restaging, therapy monitoring, and prognostic prediction of ovarian cancer. For ovarian cancer surveilla
Externí odkaz:
https://doaj.org/article/a4bc901765c54c19a8c598aacd1adbc1
Publikováno v:
International Journal of Women's Health, Vol Volume 15, Pp 1047-1057 (2023)
Wanyi Chen,1,* Po-Han Fang,2,* Bin Zheng,3 Yue Liang,1 Yiwen Mao,1 Xuefeng Jiang,1 Qionglan Tang4 1Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University, Guangzhou, People’s Republic of China; 2Internati
Externí odkaz:
https://doaj.org/article/db66bebd2fd64b80ae02dc7edae0d75a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Carboplatin/pegylated liposomal doxorubicin/bevacizumab is an accepted standard anti-cancer treatment option for recurrent ovarian cancer. However, the occurrence of adverse events associated with this therapeutic regimen limits its continued clinica
Externí odkaz:
https://doaj.org/article/8ae522dd2d4648dd8fd8f5524f85b308